Mar 11 |
Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $0.7M misses by $1.24M
|
Mar 11 |
Lexicon stock rallies 18% amid FDA update, $250M private placement
|
Mar 11 |
Lexicon Pharmaceuticals GAAP EPS of -$0.20 beats by $0.02, revenue of $0.7M misses by $0.54M
|
Mar 11 |
Lexicon announces oversubscribed $250M private placement of equity securities
|
Mar 11 |
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 11 |
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
|
Mar 11 |
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
|
Mar 11 |
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
|
Feb 29 |
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
|
Feb 22 |
15 Hot Penny Stocks On the Move
|